지혈 밸브 시장 : 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Hemostasis Valve Market was valued at USD 180.2 million in 2024 and is estimated to grow at a CAGR of 5.4% to reach USD 304.6 million by 2034, driven by the rising need to facilitate the use of guidewires and catheters during minimally invasive surgeries while controlling blood loss. As the healthcare sector continues to shift toward less invasive treatment options, the importance of blood management tools like hemostasis valves is becoming more prominent. The steady increase in cardiovascular diseases worldwide, fueled by aging populations, sedentary lifestyles, and poor dietary habits, has significantly boosted the demand for catheter-based interventions.

Procedures such as angioplasties, stent placements, and valve replacements are performed at a growing rate, creating a heightened need for reliable, high-performance hemostasis valves that can maintain a sealed access point while allowing smooth device movement. Surgeons and interventionalists increasingly favor technologies that simplify complex procedures and enhance patient outcomes, driving steady innovation in valve design, durability, and ease of operation. Additionally, rising healthcare investments, the expanding global geriatric population, and the growing acceptance of minimally invasive surgeries are poised to sustain the market's upward trajectory over the next decade.

The increasing preference for minimally invasive procedures across cardiology and neurology further supports the widespread adoption of hemostasis valves. These procedures are now considered the standard of care, offering benefits like reduced patient trauma, shorter hospital stays, and lower postoperative risks. As interventional procedures become more complex, clinicians are prioritizing next-generation hemostasis valves featuring enhanced sealing capabilities, one-handed operation, and broad compatibility with various catheter sizes and devices.

By product type, hemostasis valve Y-connectors dominated the market in 2024, generating USD 72 million in revenue. Their widespread use comes from their adaptability during complex interventions, especially those that require the concurrent use of multiple instruments. Y-connectors allow practitioners to manage blood flow effectively and minimize blood loss during vascular access procedures. Continuous improvements in design, including better sealing and increased device durability, have made these connectors more reliable for high-precision tasks in minimally invasive environments.

Based on application, the angiography segment captured the largest market share of 64.2% in 2024, accounting for USD 115.7 million. Hemostasis valves are essential during angiographic procedures for controlling blood flow and maintaining a secure seal when inserting and withdrawing catheters. Their use reduces blood loss and procedural complications, making them indispensable tools during contrast injections and vessel imaging. The rise of advanced imaging technologies further boosts demand for high-performance valves that offer reliability and ease of handling.

North America led the global hemostasis valve market, reaching USD 73.6 million in 2024, fueled by the surge in minimally invasive procedures in cardiology and neurology. Increasing rates of hospitalization due to chronic diseases continue to drive the adoption of catheter-based interventions, directly impacting the demand for advanced hemostasis valve technologies. The U.S. maintains leadership, backed by a strong healthcare infrastructure, government support for medical innovation, and a concentrated presence of leading industry players.

Key players shaping the Global Hemostasis Valve Market landscape include Shenzhen Antmed, Abbott Laboratories, Lepu Medical Technology, Boston Scientific, Vygon, Nipro Medical, B. Braun Melsungen, DeRoyal Industries, SCW Medicath, Freudenberg Medical, Argon Medical Devices, Terumo, Teleflex, Merit Medical Systems, and Beijing Demax Medical Technology. Companies are focusing on advancing product durability, lowering insertion resistance, and enhancing one-handed operational designs. Leaders continue to expand portfolios with pressure-resistant valve options and greater catheter compatibility while building strategic alliances with hospitals, diagnostic centers, and global distributors to strengthen market reach and foster long-term growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cardiovascular diseases
    • 3.2.1.2 Growing demand for minimally invasive surgeries
    • 3.2.1.3 Technological advancement in hemostasis valve
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Lack of skilled professionals
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Technological landscape
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Hemostasis valve Y-connectors
• 5.3 Double Y-connector hemostasis valves
• 5.4 One-handed hemostasis valves
• 5.5 Other product types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Angiography
• 6.3 Angioplasty

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers (ASCs)
• 7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Argon Medical Devices
• 9.2 Abbott Laboratories
• 9.3 B. Braun Melsungen
• 9.4 Beijing Demax Medical Technology
• 9.5 Boston Scientific
• 9.6 DeRoyal Industries
• 9.7 Freudenberg Medical
• 9.8 Lepu Medical Technology
• 9.9 Merit Medical Systems
• 9.10 Nipro Medical
• 9.11 SCW Medicath
• 9.12 Shenzhen Antmed
• 9.13 Teleflex
• 9.14 Terumo
• 9.15 Vygon